Lota Zoth Acquires 31,000 Shares of enGene Therapeutics
Lota Zoth purchased 31,000 shares of enGene Therapeutics Inc. on June 16, 2026.
Key Points
- Lota Zoth bought 31,000 shares of enGene Therapeutics Inc. on June 16, 2026, with no disclosed transaction value.
- enGene Therapeutics, trading on NasdaqCM under ENGN, has a market cap of approximately $117.2 million and a 52-week range between $1.40 and $12.25.
- The company focuses on genetic treatments for bladder cancer and has a forward P/E ratio that is not meaningful due to negative earnings.
On June 16, 2026, Lota Zoth acquired 31,000 shares of enGene Therapeutics Inc. (NasdaqCM:ENGN). The transaction did not have a disclosed value, and the stock was trading around $1.75 at the time.
enGene Therapeutics Stock Snapshot
Shares of enGene Therapeutics Inc. are listed on the Nasdaq Capital Market under the ticker ENGN. The company has a market capitalization of about $117.2 million. Its shares have traded as low as $1.40 and as high as $12.25 over the past year. The stock's 50-day moving average is approximately $4.33, while the 200-day moving average is around $7.13. enGene has a current ratio of 12.57 and a quick ratio of 12.07, with a debt-to-equity ratio of 13.07.
About enGene Therapeutics Inc.
enGene Therapeutics Inc. is a biotechnology company based in Montreal, Canada. It specializes in developing genetic medicines, focusing on treatments for bladder cancer. The company's lead product candidate, detalimogene voraplasmid, is aimed at treating non-muscle invasive bladder cancer. enGene also has another product, LEGEND, which is in Phase 2 trials. The company was previously known as enGene Holdings Inc. and adopted its current name in April 2026. Under the leadership of CEO Ronald H. W. Cooper, enGene employs 81 people.
Bottom Line
Lota Zoth's recent purchase of shares in enGene Therapeutics highlights ongoing interest in the company, despite its current challenges. enGene is focused on innovative treatments for bladder cancer, a niche that could offer potential growth opportunities. Investors will continue to monitor the company's progress as it moves forward with its clinical trials. As always, it's important to note that insider transactions are disclosed after they occur and may not reflect future actions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.